Welcome to Micromachinery for Cell Engineering and
Physiology at University of Notre Dame
|
We research on diagnosis and therapy in cancer. For diagnosis, we are developing a ultrasound contrast agent. Ultrasound is directly applicable to in vivo imaging due to deep penetration depth. For therapeutic strategies, we are developing a device by integrating a microfluidic chip and ultrasonic transducers to engineer cells, such as T cells, to express specific biomarkers to increase anti-tumor activity. By engineering those cells in vitro, we can reinfuse those engineered cells into a patient’s body to treat cancers. With our research, We hope to improve the quality of life for many people with better cancer treatments and even cures.
|
Ultrasound |
Contrast Enhanced Ultrasound (CEUS) Imaging |
|
Ultrasonic transducers and microfluidic chips to develop integrated device to engineer cells for patient-specific therapy.
Cell Engineering/ Intracellular delivery
|
Early stage cancer detection by using genetically encoded Ultrasound_contrast agents.
|
Protein discovery to manipulate cells using ultrasound
Drug delivery using targeted nanomaterials
Our Research are supported by NIH, NSF, Advanced Diagnostics & Therapeutics, and University of Notre Dame
|
|
|
|
Recruitment and Openings
We have two to three openings. We are looking for motivated, active, and innovative PhD graduate students and/or postdoctoral fellows. Any qualified and energetic students to pursue PhD degrees and researchers and scientists to continue their science in super-resolution ultrasound imaging algorithm development, genetically encoded gas vesicles, the development of intracellular delivery device development for immunotherapy are more than welcome to Yoon lab. Particularly, we are looking for a proactive, idea blinking, and self-motivated people to pursue our mission for cancer diagnosis and therapy.
1. Microfluidic chip and microtransducer for immunotherapy application: The first phase is the development of an integrated device using a microfluidics and a transducer. The second phase is in vitro and in vivo verification. This is a five year project and a complete project from device development to in vivo verification for immunotherapy applications.
2. Super-resolution ultrasound imaging and genetically encoded gas vesicles development for cancer diagnosis: Beamforming algorithm development is the first part. This part spans from the adaptation of mathematical theory to in vivo ultrasound imaging of small animals. The first part is mainly performing ex vivo and in vivo imaging and improve the imaging quality using commercial ultrasound imaging system. The second part is the development of genetically encoded gas vesicles to increase specificity and sensitivity of cancer diagnosis. We are developing various gene circuits for the visualization of various biomarkers for prognostic purposes.
Please send your interests and CV to Prof. Sangpil Yoon (syoon4@nd.edu)